---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-048827"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:35:28.734675+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vistagen completes PALISADE-3 Phase 3 trial; topline results due by year end

## Summary
- Last patient completed randomized, double-blind, placebo-controlled portion of PALISADE-3 for fasedienol in social anxiety disorder; open-label extension ongoing.
- Topline results for PALISADE-3 expected in Q4 2025; PALISADE-4 topline anticipated in H1 2026.
- PALISADE-3 uses same design as positive PALISADE-2 trial (SUDS primary endpoint); FDA Fast Track designation in place.
- Successful PALISADE-3 or -4 could support NDA submission for first acute treatment for social anxiety disorder (over 30M patients).

## SEC filing metadata
- accession: 0001628280-25-048827
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828025048827/0001628280-25-048827-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828025048827/vtgn-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-048827
- JSON: https://secwatch.observer/filing/0001628280-25-048827.json
- Plain text: https://secwatch.observer/filing/0001628280-25-048827.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.